EUVIMEDEUVIMED entdecken
Crossref

Evodiamine-Based Nitroreductase Responsive Theranostic Agents for Treatment of Colon Cancer

Keliang Li, Yuhang Sun, Zonglin Ma, Yuping Chen, Xinglin Li, Guoqiang Dong, Dan Liu, Chunquan Sheng iD, Shanchao Wu iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Keliang Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Second Military Medical University (Naval Medical Un…. Hauptthemen laut MEDLINE: Nitroreductases, Colonic Neoplasms, Antineoplastic Agents, Theranostic Nanomedicine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Rising-Star Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia is a state of low oxygen tension that is found in numerous solid tumors. Generally, nitroreductase (NTR) is overexpressed and directly correlated with the hypoxic status in solid tumors, supporting the hypothesis that prodrug could be activated by intracellular NTR and lead to potential antitumor therapy. Herein, evodiamine-based hypoxia-targeting theranostic agents were developed to enhance the antitumor efficacy. These agents are activated by NTR-mediated p-nitrobenzyl reduction, enabling simultaneous fluorophore activation for imaging and therapeutic agent (3-fluoro-10-hydroxyl-evodiamine) release for solid tumor treatment. After a systemic test, these theranostic agents were verified to be selectively activated by NTR with excellent fluorescence properties and antitumor potency. In particular, Probe-2 exhibited excellent in vivo antitumor activity (tumor growth inhibition value (TGI) = 76.1%) in HCT116 xenograft nude mice with favorable tumor-targeted properties and low toxicity. Thus, this NTR-responsive theranostic agent provides a platform for constructing prodrugs to release monitoring and active substances controlled by the hypoxic status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitroreductasesColonic NeoplasmsAntineoplastic AgentsTheranostic NanomedicineQuinazolinesHumansAnimalsMice, NudeMiceProdrugsMice, Inbred BALB CXenograft Model Antitumor AssaysHCT116 Cells

Substanzen

NitroreductasesevodiamineAntineoplastic AgentsQuinazolinesProdrugs

Autor:innen und Institutionen

  • The Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Second Military Medical University (Naval Medical University), Shanghai 200433, China.
  • Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.

ORCID-Profile: Chunquan Sheng, Shanchao Wu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Shanghai Rising-Star Program

Zitieren

APA

Li, K., Sun, Y., Ma, Z., Chen, Y., Li, X., Dong, G., Liu, D., Sheng, C., & Wu, S. (2025). Evodiamine-Based Nitroreductase Responsive Theranostic Agents for Treatment of Colon Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02822

Vancouver

Li K, Sun Y, Ma Z, Chen Y, Li X, Dong G, et al. Evodiamine-Based Nitroreductase Responsive Theranostic Agents for Treatment of Colon Cancer. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02822

BibTeX
@article{Li2025,
  author = {Li, Keliang and Sun, Yuhang and Ma, Zonglin and Chen, Yuping and Li, Xinglin and Dong, Guoqiang and Liu, Dan and Sheng, Chunquan and Wu, Shanchao},
  title = {Evodiamine-Based Nitroreductase Responsive Theranostic Agents for Treatment of Colon Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02822}
}
Kostenlos starten →